Table 5.
Associations | Level of evidence | Level of conclusion | ||||
Inflammatory signs—pain sensitivity | A1 | A2 | B | C | D | |
Effusion/synovitis | Neogi et al50[+] | Petersen et al49[+] | Sofat et al47[ns] | 2 | ||
BMLs | Neogi et al50[ns] | Sofat et al47[ns] | 2 | |||
Pro-inflammatory cytokines | 4 | |||||
IL-1β | Lee et al44[ns] | |||||
IL-6 | Imamura et al43[ns] | |||||
Lee et al44[+] | ||||||
TNF-α | Imamura et al43[ns] | |||||
Lee et al44[+] | ||||||
CRP | Arendt-Nielsen et al42[+] | Lee et al44[+] | 3 | |||
Inflammatory signs—neuropathic-like pain | ||||||
Effusion/synovitis | Radojčić et al46[+] | 4 | ||||
Pro-inflammatory cytokines | 4 | |||||
IL-1β | Li et al45[ns] | |||||
Tchetina et al48[+] | ||||||
IL-6 | Li et al45[ns] | |||||
Radojčić et al46[ns] | ||||||
TNF-α | Li et al45[ns] | |||||
Tchetina et al48[+] |
Level of evidence: A1=systematic reviews and meta-analyses, based on minimally two independent A2 studies; A2=prospective cohort studies with sufficient sample size and follow-up; adequately controlled for confounding factors and precluding selective loss to follow-up; B=prospective cohort studies, but lacking the quality criteria of A2; retrospective cohort studies and case–control studies; C=non-comparative studies; D=expert opinion. [+] Significant positive association. [ns] Not significant association. [-] Significant negative association.
Level of conclusion: 1=one A1 or at least two independent A2 studies that support each other’s conclusions and do not show conflicting evidence; 2=one A2 or at least two independent B studies that support each other’s conclusions and do not show conflicting evidence; 3=one B or at least two C studies that support each other’s conclusions and do not show conflicting evidence; 4=research at level C or two or more independent studies at higher level that do not support each other’s conclusions and hence, show conflicting evidence; consensus=there is no evidence, but consensus (level D); no conclusions=there is no evidence and no consensus.
BMLs, bone marrow lesions; CRP, C reactive protein; IL, interleukin; TNF-α, tumour necrosis factor-α.